1
|
Potjewyd FM, Annor‐Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery. Alzheimers Dement (N Y) 2022; 8:e12246. [PMID: 35475262 PMCID: PMC9019904 DOI: 10.1002/trc2.12246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 11/29/2021] [Accepted: 12/13/2021] [Indexed: 06/14/2023]
Abstract
Introduction The portfolio of novel targets to treat Alzheimer's disease (AD) has been enriched by the Accelerating Medicines Partnership Program for Alzheimer's Disease (AMP AD) program. Methods Publicly available resources, such as literature and databases, enabled a data-driven effort to identify existing small molecule modulators for many protein products expressed by the genes nominated by AMP AD and suitable positive control compounds to be included in the set. Compounds contained within the set were manually selected and annotated with associated published, predicted, and/or experimental data. Results We built an annotated set of 171 small molecule modulators targeting 98 unique proteins that have been nominated by AMP AD consortium members as novel targets for the treatment of AD. The majority of compounds included in the set are inhibitors. These small molecules vary in their quality and should be considered chemical tools that can be used in efforts to validate therapeutic hypotheses, but which will require further optimization. A physical copy of the AD Informer Set can be requested on the Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) website. Discussion Small molecules that enable target validation are important tools for the translation of novel hypotheses into viable therapeutic strategies for AD.
Collapse
Affiliation(s)
- Frances M. Potjewyd
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryStructural Genomics ConsortiumChapel HillNorth CarolinaUSA
| | - Joel K. Annor‐Gyamfi
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryStructural Genomics ConsortiumChapel HillNorth CarolinaUSA
| | - Jeffrey Aubé
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Shaoyou Chu
- Department of MedicineDivision of Clinical PharmacologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Ivie L. Conlon
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Kevin J. Frankowski
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Shiva K. R. Guduru
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Brian P. Hardy
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Megan D. Hopkins
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Chizuru Kinoshita
- Department of Laboratory Medicine and PathologyUniversity of WashingtonSeattleWashingtonUSA
- Institute for Stem Cell and Regenerative MedicineUniversity of WashingtonSeattleWashingtonUSA
| | - Dmitri B. Kireev
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Emily R. Mason
- Department of MedicineDivision of Clinical PharmacologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Charles T. Moerk
- Department of Laboratory Medicine and PathologyUniversity of WashingtonSeattleWashingtonUSA
- Institute for Stem Cell and Regenerative MedicineUniversity of WashingtonSeattleWashingtonUSA
| | - Felix Nwogbo
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Kenneth H. Pearce
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Timothy I. Richardson
- Department of MedicineDivision of Clinical PharmacologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - David A. Rogers
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Disha M. Soni
- Department of MedicineDivision of Clinical PharmacologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Michael Stashko
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Xiaodong Wang
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Carrow Wells
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryStructural Genomics ConsortiumChapel HillNorth CarolinaUSA
| | - Timothy M. Willson
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryStructural Genomics ConsortiumChapel HillNorth CarolinaUSA
| | - Stephen V. Frye
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryCenter for Integrative Chemical Biology and Drug DiscoveryChapel HillNorth CarolinaUSA
| | - Jessica E. Young
- Department of Laboratory Medicine and PathologyUniversity of WashingtonSeattleWashingtonUSA
- Institute for Stem Cell and Regenerative MedicineUniversity of WashingtonSeattleWashingtonUSA
| | - Alison D. Axtman
- UNC Eshelman School of PharmacyDivision of Chemical Biology and Medicinal ChemistryStructural Genomics ConsortiumChapel HillNorth CarolinaUSA
| |
Collapse
|
2
|
Potjewyd FM, Annor‐Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology. A&D Transl Res & Clin Interv 2022; 8:e12253. [PMID: 35434254 PMCID: PMC9005681 DOI: 10.1002/trc2.12253] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 11/29/2021] [Accepted: 12/15/2021] [Indexed: 12/03/2022]
Abstract
Introduction A chemogenomic set of small molecules with annotated activities and implicated roles in Alzheimer's disease (AD) called the AD Informer Set was recently developed and made available to the AD research community: https://treatad.org/data‐tools/ad‐informer‐set/. Methods Small subsets of AD Informer Set compounds were selected for AD‐relevant profiling. Nine compounds targeting proteins expressed by six AD‐implicated genes prioritized for study by Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT‐AD) teams were selected for G‐protein coupled receptor (GPCR), amyloid beta (Aβ) and tau, and pharmacokinetic (PK) studies. Four non‐overlapping compounds were analyzed in microglial cytotoxicity and phagocytosis assays. Results The nine compounds targeting CAPN2, EPHX2, MDK, MerTK/FLT3, or SYK proteins were profiled in 46 to 47 primary GPCR binding assays. Human induced pluripotent stem cell (iPSC)‐derived neurons were treated with the same nine compounds and secretion of Aβ peptides (Aβ40 and Aβ42) as well as levels of phosphophorylated tau (p‐tau, Thr231) and total tau (t‐tau) peptides measured at two concentrations and two timepoints. Finally, CD1 mice were dosed intravenously to determine preliminary PK and/or brain‐specific penetrance values for these compounds. As a final cell‐based study, a non‐overlapping subset of four compounds was selected based on single‐concentration screening for analysis of both cytotoxicity and phagocytosis in murine and human microglia cells. Discussion We have demonstrated the utility of the AD Informer Set in the validation of novel AD hypotheses using biochemical, cellular (primary and immortalized), and in vivo studies. The selectivity for their primary targets versus essential GPCRs in the brain was established for our compounds. Statistical changes in tau, p‐tau, Aβ40, and/or Aβ42 and blood–brain barrier penetrance were observed, solidifying the utility of specific compounds for AD. Single‐concentration phagocytosis results were validated as predictive of dose–response findings. These studies established workflows, validated assays, and illuminated next steps for protein targets and compounds.
Collapse
Affiliation(s)
- Frances M. Potjewyd
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA
| | - Joel K. Annor‐Gyamfi
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA
| | - Jeffrey Aubé
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Shaoyou Chu
- Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA
| | - Ivie L. Conlon
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Kevin J. Frankowski
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Shiva K. R. Guduru
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Brian P. Hardy
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Megan D. Hopkins
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Chizuru Kinoshita
- Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA
- Institute for Stem Cell and Regenerative Medicine University of Washington Seattle Washington USA
| | - Dmitri B. Kireev
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Emily R. Mason
- Department of Medicine Division of Clinical Pharmacology Indiana University School of Medicine Indianapolis Indiana USA
| | - Charles T. Moerk
- Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA
- Institute for Stem Cell and Regenerative Medicine University of Washington Seattle Washington USA
| | - Felix Nwogbo
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Kenneth H. Pearce
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Timothy I. Richardson
- Department of Medicine Division of Clinical Pharmacology Indiana University School of Medicine Indianapolis Indiana USA
| | - David A. Rogers
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Disha M. Soni
- Department of Medicine Division of Clinical Pharmacology Indiana University School of Medicine Indianapolis Indiana USA
| | - Michael Stashko
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Xiaodong Wang
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Carrow Wells
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA
| | - Timothy M. Willson
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA
| | - Stephen V. Frye
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Center for Integrative Chemical Biology and Drug Discovery Chapel Hill North Carolina USA
| | - Jessica E. Young
- Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA
- Institute for Stem Cell and Regenerative Medicine University of Washington Seattle Washington USA
| | - Alison D. Axtman
- UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA
| |
Collapse
|
3
|
Potjewyd FM, Annor‐Gyamfi JK, Guduru SKR, Nwogbo F, Rogers DA, Hopkins MD, Conlon I, Wells C, Stashko M, Hardy BP, Wang X, Frankowski K, Kireev DB, Pearce KH, Willson T, Aubé J, Frye SV, Richardson T, Young JE, Axtman AD. Generation of the AD Informer Set: Chemical tools to facilitate Alzheimer’s disease drug discovery. Alzheimers Dement 2021. [DOI: 10.1002/alz.051113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Frances M. Potjewyd
- University of North Carolina at Chapel Hill Chapel Hill NC USA
- Structural Genomics Consortium Chapel Hill NC USA
| | - Joel K. Annor‐Gyamfi
- University of North Carolina at Chapel Hill Chapel Hill NC USA
- Structural Genomics Consortium Chapel Hill NC USA
| | | | - Felix Nwogbo
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | - David A. Rogers
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | | | - Ivie Conlon
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | - Carrow Wells
- University of North Carolina at Chapel Hill Chapel Hill NC USA
- Structural Genomics Consortium Chapel Hill NC USA
| | - Michael Stashko
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | - Brian P. Hardy
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | - Xiaodong Wang
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | | | | | | | - Tim Willson
- University of North Carolina at Chapel Hill Chapel Hill NC USA
- Structural Genomics Consortium Chapel Hill NC USA
| | - Jeff Aubé
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | - Stephen V. Frye
- University of North Carolina at Chapel Hill Chapel Hill NC USA
| | | | | | - Alison D. Axtman
- University of North Carolina at Chapel Hill Chapel Hill NC USA
- Structural Genomics Consortium Chapel Hill NC USA
| |
Collapse
|
4
|
Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D. Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. J Am Chem Soc 2019; 141:15700-15709. [PMID: 31497954 DOI: 10.1021/jacs.9b08660] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Controlling which particular members of a large protein family are targeted by a drug is key to achieving a desired therapeutic response. In this study, we report a rational data-driven strategy for achieving restricted polypharmacology in the design of antitumor agents selectively targeting the TYRO3, AXL, and MERTK (TAM) family tyrosine kinases. Our computational approach, based on the concept of fragments in structural environments (FRASE), distills relevant chemical information from structural and chemogenomic databases to assemble a three-dimensional inhibitor structure directly in the protein pocket. Target engagement by the inhibitors designed led to disruption of oncogenic phenotypes as demonstrated in enzymatic assays and in a panel of cancer cell lines, including acute lymphoblastic and myeloid leukemia (ALL/AML) and nonsmall cell lung cancer (NSCLC). Structural rationale underlying the approach was corroborated by X-ray crystallography. The lead compound demonstrated potent target inhibition in a pharmacodynamic study in leukemic mice.
Collapse
Affiliation(s)
- Chenxiao Da
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| | - Dehui Zhang
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| | - Michael Stashko
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| | - Eleana Vasileiadi
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | - Rebecca E Parker
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | - Katherine A Minson
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | - Madeline G Huey
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | - Justus M Huelse
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | | | | | - Jacqueline Norris-Drouin
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| | | | | | | | - Deborah DeRyckere
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | | | - Douglas K Graham
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics , Emory University , Atlanta , Georgia 30322 , United States
| | - Stephen V Frye
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| | - Xiaodong Wang
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| | - Dmitri Kireev
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina 27599-7363 , United States
| |
Collapse
|
5
|
Simpson C, Jones NG, Hull-Ryde EA, Kireev D, Stashko M, Tang K, Janetka J, Wildman SA, Zuercher WJ, Schapira M, Hui R, Janzen W, Sibley LD. Identification of small molecule inhibitors that block the Toxoplasma gondii rhoptry kinase ROP18. ACS Infect Dis 2016; 2:194-206. [PMID: 27379343 PMCID: PMC4930114 DOI: 10.1021/acsinfecdis.5b00102] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The protozoan parasite Toxoplasma gondii secretes a family of serine-threonine protein kinases into its host cell in order to disrupt signaling and alter immune responses. One prominent secretory effector is the rhoptry protein 18 (ROP18), a serine-threonine kinase that phosphorylates immunity related GTPases (IRGs) and hence blocks interferon gamma-mediated responses in rodent cells. Previous genetic studies show that ROP18 is a major virulence component of T. gondii strains from North and South America. Here, we implemented a high throughput screen to identify small molecule inhibitors of ROP18 in vitro and subsequently validated their specificity within infected cells. Although ROP18 was not susceptible to many kinase-directed inhibitors that affect mammalian kinases, the screen identified several sub micromolar inhibitors that belong to three chemical scaffolds: oxindoles, 6-azaquinazolines, and pyrazolopyridines. Treatment of interferon gamma-activated cells with one of these inhibitors enhanced immunity related GTPase recruitment to wild type parasites, recapitulating the defect of Δrop18 mutant parasites, consistent with targeting ROP18 within infected cells. These compounds provide useful starting points for chemical biology experiments or as leads for therapeutic interventions designed to reduce parasite virulence.
Collapse
Affiliation(s)
- Catherine Simpson
- Center for Integrative Chemical Biology and Drug Discovery, UNC
Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road,
CB#7363, Chapel Hill, NC 27599-7363
| | - Nathaniel G. Jones
- Department of Molecular Microbiology, Washington University Sch.
Med. St. Louis MO 63110
| | - Emily A. Hull-Ryde
- Center for Integrative Chemical Biology and Drug Discovery, UNC
Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road,
CB#7363, Chapel Hill, NC 27599-7363
| | - Dmitri Kireev
- Center for Integrative Chemical Biology and Drug Discovery, UNC
Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road,
CB#7363, Chapel Hill, NC 27599-7363
| | - Michael Stashko
- Center for Integrative Chemical Biology and Drug Discovery, UNC
Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road,
CB#7363, Chapel Hill, NC 27599-7363
| | - Keliang Tang
- Department of Molecular Microbiology, Washington University Sch.
Med. St. Louis MO 63110
| | - Jim Janetka
- Department of Biochemistry and Molecular Biophysics, Washington
University Sch. Med. St. Louis MO 63110
| | - Scott A. Wildman
- Department of Biochemistry and Molecular Biophysics, Washington
University Sch. Med. St. Louis MO 63110
| | - William J. Zuercher
- SGC-UNC, Division of Chemical Biology and Medicinal Chemistry, UNC
Eshelman School of Pharmacy, 120 Mason Farm Rd, 1070H Genetic Medicine Building,
University of North Carolina, NC 27599-7363
| | - Matthieu Schapira
- Structural Genomics Consortium, University of Toronto, MaRS South
Tower, 101 College St, Toronto, ON, M5G 1L7, Canada
- Department of Pharmacology and Toxicology, University of Toronto, 1
King’s College Circle, Toronto, ON M5S 1A8, Canada
| | - Raymond Hui
- Structural Genomics Consortium, University of Toronto, MaRS South
Tower, 101 College St, Toronto, ON, M5G 1L7, Canada
- Toronto General Hospital Research Institute, 200 Elizabeth St.,
Toronto, ON M5G 2C4, Canada
| | - William Janzen
- Center for Integrative Chemical Biology and Drug Discovery, UNC
Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road,
CB#7363, Chapel Hill, NC 27599-7363
| | - L. David Sibley
- Department of Molecular Microbiology, Washington University Sch.
Med. St. Louis MO 63110
| |
Collapse
|
6
|
Wright BD, Simpson C, Stashko M, Kireev D, Hull-Ryde EA, Zylka MJ, Janzen WP. Development of a High-Throughput Screening Assay to Identify Inhibitors of the Lipid Kinase PIP5K1C. ACTA ACUST UNITED AC 2014; 20:655-62. [PMID: 25534829 DOI: 10.1177/1087057114564057] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 11/23/2014] [Indexed: 11/16/2022]
Abstract
Phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks) regulate a variety of cellular processes, including signaling through G protein-coupled receptors (GPCRs), endocytosis, exocytosis, and cell migration. These lipid kinases synthesize phosphatidylinositol 4,5-bisphosphate (PIP2) from phosphatidylinositol 4-phosphate [PI(4)P]. Because small-molecule inhibitors of these lipid kinases did not exist, molecular and genetic approaches were predominantly used to study PIP5K1 regulation of these cellular processes. Moreover, standard radioisotope-based lipid kinase assays cannot be easily adapted for high-throughput screening. Here, we report a novel, high-throughput, microfluidic mobility shift assay to identify inhibitors of PIP5K1C. This assay uses fluorescently labeled phosphatidylinositol 4-phosphate as the substrate and recombinant human PIP5K1C. Our assay exhibited high reproducibility, had a calculated adenosine triphosphate Michaelis constant (Km) of 15 µM, performed with z' values >0.7, and was used to screen a kinase-focused library of ~4700 compounds. From this screen, we identified several potent inhibitors of PIP5K1C, including UNC3230, a compound that we recently found can reduce nociceptive sensitization in animal models of chronic pain. This novel assay will allow continued drug discovery efforts for PIP5K1C and can be adapted easily to screen additional lipid kinases.
Collapse
Affiliation(s)
- Brittany D Wright
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA National Center for Advancing Translational Science, Rockville, MD 20850
| | - Catherine Simpson
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Michael Stashko
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Dmitri Kireev
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Emily A Hull-Ryde
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Mark J Zylka
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Department of Cell Biology and Physiology, UNC Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - William P Janzen
- Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| |
Collapse
|
7
|
Abstract
Many hormone or growth factor receptors signal via the activation of protein-tyrosine kinases and phosphatases. Alteration of the phosphorylation state of tyrosine residues in certain proteins can directly regulate enzyme activity or cause formation of protein complexes necessary for transducing intracellular signals. Genetic and biochemical evidence also implicates protein-tyrosine phosphatases in several disease processes, including negative regulation of insulin receptor signaling at the level of the insulin receptor and perhaps in signaling at the IRS-1 level. The expression of protein tyrosine phosphatase-1B (PTP1B) is elevated in muscle and adipose tissue in insulin-resistant states both in man and rodents suggesting that PTP1B may play a role in the insulin-resistant state associated with diabetes and obesity. As described in this unit, PTP1B activity can be determined with the small molecule substrate, p-nitrophenyl phosphate (pNPP), in which the cleavage of the phosphate results in production of p-nitrophenol (pNP) and an increase in absorbance at 405 nm. Alternatively, PTP1B activity can be measured as described using model phosphotyrosyl-containing peptide substrates in which the release of free phosphate from the peptide is determined using a malachite green colorimetric assay.
Collapse
Affiliation(s)
- T Lubben
- Abbott Laboratories, Abbott Park, IL, USA
| | | | | | | | | |
Collapse
|
8
|
Stashko M, Lubben T, Clampit J, Wang S, Sun C, Serby M, Liu B, Xin Z, Liu G, Trevillyan J. A Luciferase Assay to Assess JNK1 Activation. FASEB J 2006. [DOI: 10.1096/fasebj.20.4.a54-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Michael Stashko
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Thomas Lubben
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Jill Clampit
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Sanyi Wang
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Chaohong Sun
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Michael Serby
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Bo Liu
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Zhili Xin
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - Gang Liu
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| | - James Trevillyan
- 47R Metabolic Disease ResearchAbbott Laboratories200 Abbott Park Rd. AP10‐1, Abbott ParkIL60064
| |
Collapse
|
9
|
Coghlan MJ, Kym PR, Elmore SW, Wang AX, Luly JR, Wilcox D, Stashko M, Lin CW, Miner J, Tyree C, Nakane M, Jacobson P, Lane BC. Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity. J Med Chem 2001; 44:2879-85. [PMID: 11520196 DOI: 10.1021/jm010228c] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A novel class of functional ligands for the human glucocorticoid receptor is described. Substituents in the C-10 position of the tetracyclic core are essential for glucocorticoid receptor (GR) selectivity versus other steroid receptors. The C-5 position is derivatized with meta-substituted aromatic groups, resulting in analogues with a high affinity for GR (K(i) = 2.4-9.3 nM) and functional activity comparable to prednisolone in reporter gene assays of glucocorticoid-mediated gene transcription. The biological activity of these novel quinolines was also prednisolone-equivalent in whole cell assays of glucocorticoid function, and compound 13 was similar to prednisolone (po ED(50) = 2.8 mpk for 13 vs ED(50) = 1.2 mpk for prednisolone) in a rodent model of asthma (sephadex-induced eosinophil influx).
Collapse
Affiliation(s)
- M J Coghlan
- Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Shiosaki K, Lin CW, Kopecka H, Bianchi B, Miller T, Stashko M, Witte D. Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors. J Med Chem 1997; 40:1169-72. [PMID: 9089338 DOI: 10.1021/jm960509y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We previously reported novel Boc-CCK-4 (Boc-Trp-Met-Asp-Phe-NH2) derivatives possessing the general structure Boc-Trp-Lys[N epsilon-CO-NH-(R-Ph)]-Asp-Phe-NH2 (Shiosaki et al. J. Med. Chem. 1991, 34, 2837-2842). In contrast to Boc-CCK-4, which is 70-fold selective for the CCK-B receptor, the modified lysine-bearing tetrapeptides were highly potent and selective full agonists at the CCK-A receptor. Further investigation of the structure-activity profile following modification of the substituted phenylurea moiety appended off the lysine revealed that moving certain substituents, e.g. nitro or acetyl, from the 2- or 3-position on the phenyl ring to the 4-position, a relatively minor and subtle structural modification within the tetrapeptide, resulted in loss of CCK-A receptor selectivity and development of a trend toward CCK-B selectivity. These tetrapeptides, e.g. Boc-Trp-Lys[N epsilon-CO-NH-(4-NO2-Ph)]-Asp-Phe-NH2 and Boc-Trp-Lys[N epsilon-CO-NH-(4-Ac-Ph)]-Asp-Phe-NH2, were full agonists relative to CCK-8 in stimulating intracellular calcium mobilization in a cell line that expresses the CCK-B receptor.
Collapse
Affiliation(s)
- K Shiosaki
- Neuroscience Discovery Research, Abbott Laboratories, Abbott Park, Illinois 60064, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther 1996; 276:150-60. [PMID: 8558425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
(-)-Trans 9,10-hydroxy-2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5- azacyclopent-1-ena[c]phenanthrene hydrochloride (A-86929) is a potent and selective full agonist at the dopamine (DA) D1-like receptor. Judging by its binding affinities to the D1 and D2 classes of receptors, the compound is approximately 20-fold D1 receptor-selective, whereas relative potencies based on functional in vitro assays indicate that A-86929 is greater than 400-fold D1-selective. A-86929 has moderate to weak (Ki > 1 microM) affinity at other monoaminergic and peptidergic receptors, at ion channels and at monoamine uptake sites. The catechol of A-86929 was bis-acetylated to produce the prodrug, (-)-trans 9,10-acetoxy-2-propyl-4,5,5a,6,7,11-b-hexahydro-3-thia- 5-azacyclopent-1-ena[c]phenanthrene hydrochloride (ABT-431), which is more chemically stable yet is rapidly converted to the parent compound with a half-life of less than 1 min in plasma. Both A-86929 and ABT-431 produced contralateral rotation in rats bearing unilateral 6-hydroxydopamine lesions, with ED50 values of 0.24 mumol/kg s.c. and 0.54 mumol/kg s.c., respectively. A-86929 and ABT-431 improved behavioral disability scores and increased locomotor activity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned marmoset model of Parkinson's disease in a dose-dependent manner (the minimum effective dose was 0.10 mumol/kg s.c.). When administered three times daily for 30 consecutive days to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned marmosets, A-86929 significantly improved disability scores throughout the duration of the study. Current Parkinson's disease therapy includes L-dopa, which stimulates both classes of DA receptors by virtue of its conversion to DA in vivo, and direct-acting D2-selective agonists. Stimulation of the D2 receptor, which is associated with all current DA agonist-based therapies, may contribute to their dose-limiting side effects. An agent such as A-86929 (or its prodrug ABT-431), which selectively stimulates the D1 receptor, may represent a novel mechanism for Parkinson's disease therapy with the potential for an improved side-effect profile and, consequently, improved patient compliance.
Collapse
MESH Headings
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- Animals
- Antiparkinson Agents/metabolism
- Antiparkinson Agents/pharmacology
- Behavior, Animal/drug effects
- CHO Cells
- Callithrix
- Corpus Striatum/metabolism
- Corpus Striatum/ultrastructure
- Cricetinae
- Disease Models, Animal
- Dopamine Agonists/metabolism
- Dopamine Agonists/pharmacology
- Dose-Response Relationship, Drug
- Female
- Fishes
- Humans
- Kinetics
- Male
- Mice
- Parkinson Disease, Secondary/chemically induced
- Parkinson Disease, Secondary/drug therapy
- Parkinson Disease, Secondary/metabolism
- Prodrugs/metabolism
- Prodrugs/pharmacology
- Pyridines/metabolism
- Pyridines/pharmacology
- Quinolones
- Rats
- Rats, Sprague-Dawley
- Receptors, Dopamine D1/agonists
- Receptors, Dopamine D1/metabolism
- Tetrahydronaphthalenes/metabolism
- Tetrahydronaphthalenes/pharmacology
- Thiophenes
Collapse
Affiliation(s)
- K Shiosaki
- Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lin CW, Miller TR, Witte DG, Bianchi BR, Stashko M, Manelli AM, Frail DE. Characterization of cloned human dopamine D1 receptor-mediated calcium release in 293 cells. Mol Pharmacol 1995; 47:131-9. [PMID: 7838121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Dopamine (DA) D1 receptors are generally known to couple only to Gs and cAMP production. Recently, D1 receptors expressed in mouse Ltk- cells have been shown to induce cAMP production, phosphoinositide (PI) hydrolysis, and calcium mobilization [Mol. Endocrinol. 6: 1815-1824 (1992)]. To further evaluate second messenger systems that could be activated by the D1 receptor, we examined the effects of DA, (R)-(+)-SKF-38393, and DA antagonists on cAMP production and calcium release in human embryonic kidney 293 cells stably expressing three different levels (Bmax = 0.12, 1.4, and 23 pmol/mg of protein) of the human D1 receptor. DA and (R)-(+)-SKF-38393 activated cAMP production and calcium release in all three D1-293 clones, and their potency was proportional to receptor density. The efficacy of SKF-38393 was also increased with receptor density in both cAMP and calcium studies. The effect of DA on calcium release consisted of a transient peak response (< 20 sec) that declined to an ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid-sensitive plateau level above the base-line (>5 min). The effect of DA on cAMP and calcium release was selectively inhibited by SCH23390, a selective D1 antagonist, and not by spiperone, a selective D2 antagonist. DA did not induce PI hydrolysis in any of the three receptor-expressing clones. A 24-hr pretreatment with cholera toxin (2 micrograms/ml) greatly attenuated the effect of DA on cAMP formation and calcium release. To address how DA could activate calcium release without enhancing PI hydrolysis, the effects of forskolin, thapsigargin, and isoproterenol (Iso) were studied. Similarly to the effects of DA, forskolin and Iso stimulated cAMP production and calcium release from D1-293 cells. Cells that were stimulated with Iso or forskolin showed a reduced response to subsequent addition of DA. Pretreatment of D1-293 cells with thapsigargin, a selective Ca2+-ATPase inhibitor, elicited calcium release from the inositol-1, 4, 5-trisphosphate-sensitive calcium store and attenuated the response to subsequent addition of DA. Carbachol stimulated PI hydrolysis and calcium release but had little effect on cAMP production. Prestimulation with carbachol abolished the calcium response to DA, Iso, or forskolin. These studies indicate that D1 receptor-mediated calcium mobilization in 293 cells is dependent on cAMP production and the cAMP-dependent calcium store is part of the inositol-1,4,5-trisphosphate-sensitive calcium pool.
Collapse
MESH Headings
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology
- Benzazepines/metabolism
- Calcium/metabolism
- Calcium/physiology
- Cells, Cultured
- Cholera Toxin/pharmacology
- Cloning, Molecular
- Colforsin/pharmacology
- Cyclic AMP/biosynthesis
- Dopamine/pharmacology
- Humans
- Hydrolysis
- Intracellular Fluid/metabolism
- Isoproterenol/pharmacology
- Kinetics
- Phosphatidylinositols/metabolism
- Receptors, Dopamine D1/genetics
- Receptors, Dopamine D1/metabolism
- Receptors, Dopamine D1/physiology
- Stimulation, Chemical
- Tritium
Collapse
Affiliation(s)
- C W Lin
- Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064
| | | | | | | | | | | | | |
Collapse
|
13
|
Bennett MJ, Nikkel AL, Bianchi BR, Miller TR, Bednarz L, Witte DG, Stashko M, Wang SS, Gore PA, Asin KE. CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue. J Med Chem 1994; 37:1569-71. [PMID: 8201591 DOI: 10.1021/jm00037a006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Previous structure-activity studies on a series of CCK-A selective tetrapeptide agonists, typified by A-71623 (Boc-Trp-Lys(CONH-Ph-o-Me)-Asp-(N-Me)Phe-NH2), have shown that replacement of the Lys(N epsilon-carbamoyl) substituent with N epsilon-acyl substituents resulted in partial agonists with moderate to high affinities for the CCK-A receptor and that replacement of the C-terminal dipeptide with either (N-Me)Asp-Phe or (N-Me)Asp-(N-Me)Phe was highly favorable to in vitro and in vivo CCK activity. The present study demonstrates that although analogues in the epsilon-amide series that are N-methylated at the Phe position are weakly active or inactive in an in vivo rat appetite suppression assay, incorporation of (N-Me)Asp or (N-Me)Asp-(N-Me)Phe modifications in this series results in analogues with markedly improved in vivo activity. In in vitro assays, there is minimal effect of N-methylation pattern on binding affinity, whereas there is a trend toward improved functional activity in the phosphatidylinositol hydrolysis assay in analogues containing (N-Me)Asp.
Collapse
Affiliation(s)
- M J Bennett
- Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Shue YK, Tufano MD, Carrera GM, Kopecka H, Kuyper SL, Holladay MW, Lin CW, Witte DG, Miller TR, Stashko M. Double bond isosteres of the peptide bond: synthesis and biological activity of cholecystokinin (CCK) C-terminal hexapeptide analogs. Bioorg Med Chem 1993; 1:161-71. [PMID: 8081848 DOI: 10.1016/s0968-0896(00)82117-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
New and existing methodologies were used to prepare a series of modified CCK analogs in which each amide bond was replaced by a trans-alkene unit. The data indicate that every amide linkage at C-terminal tetrapeptide (CCK-4) region is crucial for biological activity. While the amide bond beyond the Trp residue in the N-terminal direction can be replaced by a trans-alkene and still retain most of the binding potency and functional activity.
Collapse
Affiliation(s)
- Y K Shue
- Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, IL 60064
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Shiosaki K, Lin CW, Leanna M, Morton HE, Miller TR, Witte D, Stashko M, Nadzan AM. Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists. Bioorg Med Chem Lett 1993. [DOI: 10.1016/s0960-894x(00)80680-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Shiosaki K, Lin CW, Kopecka H, Craig RA, Bianchi BR, Miller TR, Witte DG, Stashko M, Nadzan AM. Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues. J Med Chem 1992; 35:2007-14. [PMID: 1375964 DOI: 10.1021/jm00089a010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
A series of Boc-CCK-4 derivatives represented by the general structure Boc-Trp-Lys(N epsilon-COR)-Asp-Phe-NH2, where R is an aromatic, heterocyclic, or aliphatic group, are potent and selective CCK-A receptor agonists. These amide-bearing compounds complement the previously described urea-based tetrapeptides (Shiosaki et al. J. Med. Chem. 1991, 34, 2837-2842); structure-activity studies revealed parallel as well as divergent trends between these two series. A significant correlation was observed between pancreatic binding affinity and the resonance constant R of the phenyl substituent in one particular series of derivatives. Sulfation of phenolic amides appended onto the epsilon-amino group of the lysine did not affect affinity for the CCK-A receptor in contrast to the 500-fold increase in binding potency observed upon sulfation of CCK-8, suggesting that the lysine appendage and the sulfated tyrosine in CCK-8, both key structural elements that impart high affinity for the CCK-A receptor, are interacting differently with the receptor. The amide-bearing tetrapeptides are full agonists relative to CCK-8 in stimulating pancreatic amylase release while being partial agonists in eliciting phosphoinositide (PI) hydrolysis. Both effects were blocked by selective CCK-A receptor antagonists.
Collapse
Affiliation(s)
- K Shiosaki
- Neuroscience Research Division, Abbott Laboratories, Abbott Park, Illinois 60064
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kerwin JF, Wagenaar F, Kopecka H, Lin CW, Miller T, Witte D, Stashko M, Nadzan AM. Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors. J Med Chem 1991; 34:3350-9. [PMID: 1766000 DOI: 10.1021/jm00116a002] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The intriguing structural similarities of glutamic acid based cholecystokinin (CCK) antagonists (A-64718 and A-65186) and the benzodiazepine CCK antagonist MK-329 (L-364,718) have been reported. Efforts to include the weak CCK antagonist benzotript into this construct utilizing a similar approach have resulted in a novel series of benzotript-based hybrid antagonists N alpha-(3'-quinolylcarbonyl)-(R)-tryptophan di-n-pentylamide (9, A-67396), N alpha-(4',8'-dihydroxy-2'-quinolylcarbonyl)-(R)-tryptophan di-n-pentylamide (23, A-70276), and N alpha-(3'-quinolylcarbonyl)-(R)-5'-hydroxytryptophan di-n-pentylamide (36, A-71134) which possess respectively binding affinities of 23, 21, and 11 nM for the pancreatic CCK-A receptor and which inhibit CCK8-induced amylase secretion. Compound 9 possesses a selectivity of greater than 500-fold for the pancreatic CCK-A receptor over the CCK-B receptor.
Collapse
Affiliation(s)
- J F Kerwin
- Neuroscience Research Division, Abbott Laboratories, Abbott Park, Illinois 60064
| | | | | | | | | | | | | | | |
Collapse
|